



Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司

Lee's Pharmaceutical Trading Debut

[14 May 2010, Hong Kong] **Lee's Pharmaceutical Holdings Limited** (“**Lee's Pharmaceutical**” or the “**Group**”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“**HKEx**”) today.

Shares of Lee's Pharmaceutical were actively traded with an intra day high of HK\$4.09 per share and closing at HK\$4.05 per share. An aggregate turnover of approximately HK\$6,200,000 was traded.

Ms. Lee Siu Fong, the Chairman of the Group said, “Today, Lee's Pharmaceutical is successfully listed on the Main Board. It is a major milestone of the Group's corporate development. The Group has been listed on the Growth Enterprise Market since 15 July 2002, which is fully integrated with solid infrastructures in drug development, clinical development, and the manufacturing, sales and marketing in China with diversified perspectives. The Group has successfully introduced Italy-based groups, Sigma-tau and Vivo Ventures Fund, to be the strategic shareholders. We believe that the transfer of listing will enhance the profile of the Group and its corporate image. We expect that the transfer of listing will be beneficial to the Group's future growth, flexibility of corporate financing and business development.”



Ms. Lee Siu Fong, the Chairman of Lee's Pharmaceutical, together with the Company's directors, and member of the listing committee of the HKEx.



Ms. Lee Siu Fong, the Chairman of Lee's Pharmaceutical (right), presented souvenir to Lawrence Fok, Executive Vice President and Head of Issuer Marketing Division the HKEx (left).

Information about Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited, a biopharmaceutical company, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002, with over 15 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing and sales and marketing in China with global perspective and it currently markets six products in China. The Group focuses on many different areas such as cardiovascular diseases, dermatology, oncology, gynecology and others with more than 22 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies. The Company received approval transfer listing from GEM Board to Main Board on 14 May 2010.